Intrinsic value of OPKO Health - OPK

Previous Close

$4.85

  Intrinsic Value

$0.62

stock screener

  Rating & Target

str. sell

-87%

Previous close

$4.85

 
Intrinsic value

$0.62

 
Up/down potential

-87%

 
Rating

str. sell

We calculate the intrinsic value of OPK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  148.37
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  1,222
  1,246
  1,275
  1,308
  1,345
  1,385
  1,430
  1,479
  1,532
  1,588
  1,649
  1,715
  1,784
  1,858
  1,937
  2,021
  2,109
  2,203
  2,302
  2,407
  2,517
  2,634
  2,757
  2,887
  3,023
  3,167
  3,319
  3,478
  3,646
  3,823
  4,009
Variable operating expenses, $m
 
  1,203
  1,229
  1,258
  1,292
  1,329
  1,370
  1,414
  1,462
  1,513
  1,569
  1,557
  1,621
  1,688
  1,759
  1,835
  1,916
  2,001
  2,091
  2,186
  2,286
  2,392
  2,504
  2,622
  2,746
  2,877
  3,015
  3,159
  3,312
  3,472
  3,641
Fixed operating expenses, $m
 
  121
  124
  127
  130
  134
  137
  140
  144
  147
  151
  155
  159
  163
  167
  171
  175
  180
  184
  189
  193
  198
  203
  208
  213
  219
  224
  230
  236
  241
  248
Total operating expenses, $m
  1,295
  1,324
  1,353
  1,385
  1,422
  1,463
  1,507
  1,554
  1,606
  1,660
  1,720
  1,712
  1,780
  1,851
  1,926
  2,006
  2,091
  2,181
  2,275
  2,375
  2,479
  2,590
  2,707
  2,830
  2,959
  3,096
  3,239
  3,389
  3,548
  3,713
  3,889
Operating income, $m
  -73
  -77
  -78
  -78
  -77
  -77
  -76
  -75
  -74
  -72
  -70
  2
  5
  8
  11
  14
  18
  22
  27
  32
  37
  43
  50
  56
  64
  72
  80
  89
  99
  109
  120
EBITDA, $m
  24
  59
  60
  62
  64
  67
  70
  73
  77
  82
  87
  93
  99
  106
  113
  121
  129
  139
  148
  159
  170
  182
  195
  209
  223
  239
  255
  273
  291
  311
  331
Interest expense (income), $m
  3
  3
  3
  4
  4
  5
  6
  7
  7
  8
  10
  11
  12
  13
  15
  16
  18
  19
  21
  23
  25
  27
  29
  32
  34
  37
  39
  42
  45
  48
  52
Earnings before tax, $m
  -74
  -80
  -81
  -81
  -82
  -82
  -82
  -82
  -81
  -81
  -80
  -8
  -7
  -6
  -4
  -2
  1
  3
  6
  9
  12
  16
  20
  25
  30
  35
  41
  47
  53
  61
  68
Tax expense, $m
  -57
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  2
  2
  3
  4
  5
  7
  8
  9
  11
  13
  14
  16
  18
Net income, $m
  -25
  -80
  -81
  -81
  -82
  -82
  -82
  -82
  -81
  -81
  -80
  -8
  -7
  -6
  -4
  -2
  0
  2
  4
  7
  9
  12
  15
  18
  22
  26
  30
  34
  39
  44
  50

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  169
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  2,767
  2,652
  2,713
  2,783
  2,861
  2,948
  3,043
  3,147
  3,259
  3,380
  3,509
  3,648
  3,796
  3,954
  4,121
  4,299
  4,487
  4,687
  4,898
  5,121
  5,356
  5,604
  5,866
  6,142
  6,433
  6,739
  7,061
  7,401
  7,758
  8,134
  8,529
Adjusted assets (=assets-cash), $m
  2,598
  2,652
  2,713
  2,783
  2,861
  2,948
  3,043
  3,147
  3,259
  3,380
  3,509
  3,648
  3,796
  3,954
  4,121
  4,299
  4,487
  4,687
  4,898
  5,121
  5,356
  5,604
  5,866
  6,142
  6,433
  6,739
  7,061
  7,401
  7,758
  8,134
  8,529
Revenue / Adjusted assets
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
Average production assets, $m
  1,431
  1,460
  1,493
  1,532
  1,575
  1,622
  1,675
  1,732
  1,793
  1,860
  1,931
  2,008
  2,089
  2,176
  2,268
  2,366
  2,470
  2,580
  2,696
  2,818
  2,948
  3,084
  3,228
  3,380
  3,540
  3,709
  3,886
  4,073
  4,270
  4,476
  4,694
Working capital, $m
  221
  69
  70
  72
  74
  76
  79
  81
  84
  87
  91
  94
  98
  102
  107
  111
  116
  121
  127
  132
  138
  145
  152
  159
  166
  174
  183
  191
  201
  210
  220
Total debt, $m
  89
  88
  103
  121
  141
  163
  187
  213
  242
  272
  305
  341
  378
  418
  461
  506
  554
  604
  658
  715
  774
  837
  904
  974
  1,048
  1,126
  1,208
  1,294
  1,384
  1,480
  1,580
Total liabilities, $m
  675
  674
  689
  707
  727
  749
  773
  799
  828
  858
  891
  927
  964
  1,004
  1,047
  1,092
  1,140
  1,190
  1,244
  1,301
  1,360
  1,423
  1,490
  1,560
  1,634
  1,712
  1,794
  1,880
  1,970
  2,066
  2,166
Total equity, $m
  2,092
  1,978
  2,024
  2,076
  2,134
  2,199
  2,270
  2,347
  2,431
  2,521
  2,618
  2,721
  2,832
  2,949
  3,074
  3,207
  3,348
  3,496
  3,654
  3,820
  3,995
  4,181
  4,376
  4,582
  4,799
  5,027
  5,268
  5,521
  5,787
  6,068
  6,362
Total liabilities and equity, $m
  2,767
  2,652
  2,713
  2,783
  2,861
  2,948
  3,043
  3,146
  3,259
  3,379
  3,509
  3,648
  3,796
  3,953
  4,121
  4,299
  4,488
  4,686
  4,898
  5,121
  5,355
  5,604
  5,866
  6,142
  6,433
  6,739
  7,062
  7,401
  7,757
  8,134
  8,528
Debt-to-equity ratio
  0.043
  0.040
  0.050
  0.060
  0.070
  0.070
  0.080
  0.090
  0.100
  0.110
  0.120
  0.130
  0.130
  0.140
  0.150
  0.160
  0.170
  0.170
  0.180
  0.190
  0.190
  0.200
  0.210
  0.210
  0.220
  0.220
  0.230
  0.230
  0.240
  0.240
  0.250
Adjusted equity ratio
  0.740
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746
  0.746

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -25
  -80
  -81
  -81
  -82
  -82
  -82
  -82
  -81
  -81
  -80
  -8
  -7
  -6
  -4
  -2
  0
  2
  4
  7
  9
  12
  15
  18
  22
  26
  30
  34
  39
  44
  50
Depreciation, amort., depletion, $m
  97
  136
  138
  139
  141
  144
  146
  149
  151
  154
  157
  90
  94
  98
  102
  107
  111
  116
  121
  127
  133
  139
  145
  152
  159
  167
  175
  183
  192
  202
  211
Funds from operations, $m
  -11
  56
  57
  58
  60
  62
  64
  67
  70
  74
  78
  82
  87
  93
  98
  105
  112
  118
  126
  134
  142
  151
  160
  170
  181
  193
  205
  218
  231
  246
  261
Change in working capital, $m
  -43
  1
  2
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  7
  7
  8
  8
  8
  9
  9
  10
  10
Cash from operations, $m
  32
  55
  56
  56
  58
  59
  62
  64
  67
  70
  74
  79
  83
  88
  94
  100
  107
  113
  120
  128
  136
  144
  154
  163
  174
  185
  196
  209
  222
  236
  251
Maintenance CAPEX, $m
  0
  -64
  -66
  -67
  -69
  -71
  -73
  -75
  -78
  -81
  -84
  -87
  -90
  -94
  -98
  -102
  -107
  -111
  -116
  -121
  -127
  -133
  -139
  -145
  -152
  -159
  -167
  -175
  -183
  -192
  -202
New CAPEX, $m
  -24
  -29
  -34
  -38
  -43
  -48
  -52
  -57
  -62
  -67
  -71
  -76
  -81
  -87
  -92
  -98
  -104
  -110
  -116
  -123
  -129
  -137
  -144
  -152
  -160
  -169
  -177
  -187
  -197
  -207
  -217
Cash from investing activities, $m
  -21
  -93
  -100
  -105
  -112
  -119
  -125
  -132
  -140
  -148
  -155
  -163
  -171
  -181
  -190
  -200
  -211
  -221
  -232
  -244
  -256
  -270
  -283
  -297
  -312
  -328
  -344
  -362
  -380
  -399
  -419
Free cash flow, $m
  11
  -38
  -44
  -49
  -54
  -59
  -64
  -68
  -73
  -77
  -81
  -85
  -89
  -92
  -96
  -100
  -104
  -108
  -112
  -116
  -121
  -125
  -130
  -134
  -139
  -143
  -148
  -153
  -158
  -163
  -168
Issuance/(repayment) of debt, $m
  -44
  14
  15
  18
  20
  22
  24
  26
  28
  31
  33
  35
  38
  40
  43
  45
  48
  51
  54
  57
  60
  63
  66
  70
  74
  78
  82
  86
  91
  95
  100
Issuance/(repurchase) of shares, $m
  9
  120
  126
  133
  140
  147
  153
  159
  165
  171
  177
  112
  117
  123
  129
  134
  140
  147
  153
  160
  166
  173
  180
  188
  195
  203
  211
  219
  227
  236
  245
Cash from financing (excl. dividends), $m  
  -35
  134
  141
  151
  160
  169
  177
  185
  193
  202
  210
  147
  155
  163
  172
  179
  188
  198
  207
  217
  226
  236
  246
  258
  269
  281
  293
  305
  318
  331
  345
Total cash flow (excl. dividends), $m
  -25
  96
  98
  102
  106
  109
  113
  117
  121
  125
  129
  62
  66
  71
  75
  80
  85
  89
  95
  100
  106
  111
  117
  124
  130
  137
  145
  152
  160
  169
  177
Retained Cash Flow (-), $m
  -112
  -120
  -126
  -133
  -140
  -147
  -153
  -159
  -165
  -171
  -177
  -112
  -117
  -123
  -129
  -134
  -141
  -149
  -157
  -166
  -176
  -185
  -195
  -206
  -217
  -228
  -241
  -253
  -266
  -280
  -295
Prev. year cash balance distribution, $m
 
  154
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  130
  -28
  -31
  -34
  -37
  -40
  -42
  -44
  -46
  -48
  -50
  -51
  -52
  -54
  -55
  -56
  -59
  -63
  -66
  -70
  -74
  -78
  -82
  -86
  -91
  -96
  -101
  -106
  -112
  -118
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  124
  -26
  -27
  -28
  -29
  -29
  -28
  -28
  -26
  -25
  -24
  -22
  -20
  -18
  -16
  -14
  -13
  -12
  -10
  -9
  -8
  -6
  -5
  -4
  -4
  -3
  -2
  -2
  -1
  -1
Current shareholders' claim on cash, %
  100
  95.4
  91.0
  86.6
  82.3
  78.1
  74.2
  70.4
  66.7
  63.3
  60.1
  58.1
  56.3
  54.4
  52.7
  50.9
  49.3
  47.7
  46.1
  44.6
  43.2
  41.8
  40.4
  39.1
  37.9
  36.7
  35.5
  34.4
  33.4
  32.3
  31.4

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

FINANCIAL RATIOS  of  OPKO Health (OPK)

Valuation Ratios
P/E Ratio -108.3
Price to Sales 2.2
Price to Book 1.3
Price to Tangible Book
Price to Cash Flow 84.6
Price to Free Cash Flow 338.3
Growth Rates
Sales Growth Rate 148.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate 43.1%
Financial Strength
Quick Ratio 11
Current Ratio 0
LT Debt to Equity 3.5%
Total Debt to Equity 4.3%
Interest Coverage -24
Management Effectiveness
Return On Assets -0.9%
Ret/ On Assets - 3 Yr. Avg. -4.9%
Return On Total Capital -1.2%
Ret/ On T. Cap. - 3 Yr. Avg. -7%
Return On Equity -1.2%
Return On Equity - 3 Yr. Avg. -7.8%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 49.9%
Gross Margin - 3 Yr. Avg. 49.8%
EBITDA Margin 2.1%
EBITDA Margin - 3 Yr. Avg. -60.4%
Operating Margin -6%
Oper. Margin - 3 Yr. Avg. -62.1%
Pre-Tax Margin -6.1%
Pre-Tax Margin - 3 Yr. Avg. -74%
Net Profit Margin -2%
Net Profit Margin - 3 Yr. Avg. -65.7%
Effective Tax Rate 77%
Eff/ Tax Rate - 3 Yr. Avg. 53.2%
Payout Ratio 0%

OPK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the OPK stock intrinsic value calculation we used $1222 million for the last fiscal year's total revenue generated by OPKO Health. The default revenue input number comes from 2016 income statement of OPKO Health. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our OPK stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for OPK is calculated based on our internal credit rating of OPKO Health, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of OPKO Health.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of OPK stock the variable cost ratio is equal to 96.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $118 million in the base year in the intrinsic value calculation for OPK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for OPKO Health.

Corporate tax rate of 27% is the nominal tax rate for OPKO Health. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the OPK stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for OPK are equal to 117.1%.

Life of production assets of 22.2 years is the average useful life of capital assets used in OPKO Health operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for OPK is equal to 5.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2092 million for OPKO Health - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 558.908 million for OPKO Health is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of OPKO Health at the current share price and the inputted number of shares is $2.7 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 36.46 28.44  sell
DGX Quest Diagnost 97.12 119.06  buy
LH Laboratory of 155.84 145.26  hold
CGIX Cancer Genetic 1.95 0.18  str.sell
NVTA Invitae 8.33 0.51  str.sell
ENZ Enzo Biochem 8.52 13.20  buy
PMD Psychemedics 20.44 20.02  hold

COMPANY NEWS

▶ Why Opko Health Stock Stumbled in November   [Dec-10-17 10:26AM  Motley Fool]
▶ Is Opko Health Inc. a Buy?   [Nov-15-17 09:31PM  Motley Fool]
▶ Where Will Opko Health Inc. Be in 5 Years?   [Oct-17-17 06:03AM  Motley Fool]
▶ Opko Health inks deal to bring new drug to Japan, generate more than $100M in revenue   [Oct-12-17 03:47PM  American City Business Journals]
▶ These are the highest-paid tech executives in South Florida   [Oct-04-17 02:20PM  American City Business Journals]
▶ ETFs with exposure to OPKO Health, Inc. : October 3, 2017   [Oct-03-17 11:29AM  Capital Cube]
▶ Why Opko Health Stock Edged Higher in August   [Sep-11-17 02:00PM  Motley Fool]
▶ OPKO Health to Present at Upcoming September Conferences   [Aug-31-17 08:30AM  GlobeNewswire]
▶ We Got It Wrong With OPKO Health -- Now What?   [Aug-28-17 07:45PM  Motley Fool]
▶ Boy, Were We Wrong About Rite Aid and Opko Health   [Aug-24-17 06:15PM  Motley Fool]
▶ Billionaire Phillip Frost defends his biotech firm on 'Mad Money'   [Aug-10-17 03:50PM  American City Business Journals]
▶ OPKO Health reports 2Q loss   [Aug-08-17 09:32PM  Associated Press]
▶ ETFs with exposure to OPKO Health, Inc. : July 28, 2017   [Jul-28-17 04:37PM  Capital Cube]
▶ ETFs with exposure to OPKO Health, Inc. : July 7, 2017   [Jul-07-17 03:22PM  Capital Cube]
▶ ETFs with exposure to OPKO Health, Inc. : June 26, 2017   [Jun-26-17 04:37PM  Capital Cube]
▶ ETFs with exposure to OPKO Health, Inc. : June 16, 2017   [Jun-16-17 04:09PM  Capital Cube]
▶ OPKO Health Provides Commercial Update for RAYALDEE   [Jun-05-17 11:17AM  GlobeNewswire]
Financial statements of OPK
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.